Imagion Biosystems (ASX:IBX) Debt-to-Asset : 6.10 (As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Imagion Biosystems Debt-to-Asset?

Imagion Biosystems's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$3.18 Mil. Imagion Biosystems's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was A$0.01 Mil. Imagion Biosystems's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was A$0.52 Mil. Imagion Biosystems's debt to asset for the quarter that ended in Jun. 2024 was 6.10.

Imagion Biosystems Debt-to-Asset Historical Data

The historical data trend for Imagion Biosystems's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imagion Biosystems Debt-to-Asset Chart

Imagion Biosystems Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.18

0.05

0.46

1.56

Imagion Biosystems Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial										0.36	0.46	1.03	1.56	6.10

Competitive Comparison of Imagion Biosystems's Debt-to-Asset

For the Diagnostics & Research subindustry, Imagion Biosystems's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imagion Biosystems's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Imagion Biosystems's Debt-to-Asset falls into.

Imagion Biosystems Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Imagion Biosystems's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.546	+	3.593)	/	4.586
	=	1.56

Imagion Biosystems's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.184	+	0.007)	/	0.523
	=	6.10

Imagion Biosystems (ASX:IBX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Imagion Biosystems Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Imagion Biosystems's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Imagion Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Imagion Biosystems Ltd (ASX:IBX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

5601 Oberlin Drive, Suite 100, San Diego, CA, USA, 92121

Website

https://www.imagionbiosystems.com

Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.

Imagion Biosystems Headlines

No Headlines